Regional variations in test requiring patterns of general practitioners in Spain

MARÍA SALINAS1, MAITE LÓPEZ-GARRIGÓS1, JUILLÁN DÍAZ2, MARIO ORTUÑO3, MARTIN YAGO4, BEGOÑA LAÍZ5, ARTURO CARRATALA6, VIRTUDES CHICHILLA7, GOIZANE MARCAIDA8, ENRIQUE RODRIGUEZ-BORJA6, ANGEL ESTEBAN7, MARCOS GUAITA8, CRISTINA AGUADO5, MIGUEL A. LORENTE9, EMILIO FLORES1 & JOAQUÍN URIS10

1Department of Clinical Laboratory, Hospital Universitario de San Juan, Alicante, Spain, 2Department of Clinical Laboratory, Hospital Francesc Borja, Gandía, Valencia, Spain, 3Department of Clinical Laboratory, Hospital de la Ribera, Aleiia, Valencia, Spain, 4Department of Clinical Laboratory, Hospital de Requena, Valencia, Spain, 5Department of Clinical Laboratory, Hospital La Fe, Valencia, Spain, 6Department of Clinical Laboratory, Hospital Clinico Universitario, Valencia, Spain, 7Department of Clinical Laboratory, Hospital General Universitario de Alicante, Spain, 8Department of Clinical Laboratory, Hospital General Universitario de Valencia, Spain, 9Department of Information Systems, Roche Diagnostics, Valencia, Spain, and 10Department of Public Health, University of Alicante, Spain

Abstract

Objective. To analyze the requesting patterns for a range of laboratory tests ordered in 2009 from eight laboratories providing services to eight health areas, using appropriate indicators.

Design. Indicators measured every test request per 1,000 inhabitants, and indicators that measured the number of tests per related test requested by general practitioners were calculated. The savings generated, if each Health Care Department achieved the appropriate indicator standard, were also calculated. Laboratory Information System registers were collected, and indicators were calculated automatically in each laboratory using a data warehouse application.

Results. There was a large difference in demand for tests by health areas. The ratio of related tests also showed a great variability. The savings generated if each Health Care Department had achieved the appropriate indicator standard were €172,116 for free thyroxine, €18,289 for aspartate aminotransferase, and €62,678 for urea.

Conclusions. Considerable variability exists in general practitioners’ demand for laboratory tests.

Key words: Appropriateness, clinical chemistry, health care costs, laboratory test utilization, quality indicators

Introduction

Laboratory expenses have increased considerably in recent years (1). The growing prominence of laboratory science in diagnostic practices (2) and information technology advances that enhance test accessibility (3) increases test use. However, the same factors also predispose to over-use and misuse. The proportion of inappropriate test requests ranges from 4.5% to 95%, in studies of medical records (4) using implicit and explicit criteria. These studies are complex, difficult to conduct, and generally not cost-effective, because tests are usually a relatively low-cost item. Studies to compare ordering behavior are a less expensive way to obtain information useful for optimizing laboratory test use.
Demand for laboratory testing services by primary care in eight Health Care Departments of the Valencia Health Agency in 2009 was evaluated in this study using a range of pathology tests representing 90% of requests in general practice to compare primary care test ordering behavior.

Material and methods

The study was carried out under the auspices of the Valencia Health Agency to compare 2009 tests requested by general practitioners (GPs). The network was created by issuing two surveys to 13 laboratories (March 2008). The inclusion criteria were a common laboratory information system (LIS) (Omega, Roche Diagnostic®, Spain) and a data-warehouse application capable of stratifying LIS results among clients (in-patients, primary care patients, etc.). The eight laboratories included provide services to hospitalized, emergency, specialized, and primary care patients whose samples are obtained in primary health care centers for hematology and blood chemistry tests. The population served in each Health Care Department is shown in Table I. In stage 2, we defined and validated the registers and indicators and created a common database. In stage 3 (March 2010), the results were presented confidentially to participating hospitals at a meeting. Each laboratory representative knew only the identification of their own data. A 2-month period of reflection and suggestions followed.

Table I. Tests/1,000 inhabitants in 2009 in different health care areas. These areas received health services from different Health Care Departments to which the different laboratories participating in the study pertain.

| Health care areas (total population December 2009) | A (197,029) | B (254,233) | C (274,233) | D (271,218) | E (55,282) | F (372,138) | G (357,267) | H (233,075) |
|---------------------------------------------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| General                                           |             |             |             |             |             |             |             |             |
| Alanine aminotransferase                          | 383         | 364         | 350         | 293         | 380         | 209         | 298         | 280         |
| Alkaline phosphatase                              | 85          | 149         | 54          | 117         | 73          | 75          | 113         | 98          |
| Aspartate aminotransferase                        | 169         | 224         | 140         | 107         | 95          | 202         | 298         | 280         |
| Cholesterol                                       | 318         | 363         | 337         | 339         | 422         | 215         | 351         | 276         |
| Creatinine                                        | 511         | 364         | 345         | 324         | 387         | 219         | 311         | 276         |
| Gamma-glutamyltranspeptidase                      | 156         | 341         | 314         | 106         | 376         | 193         | 249         | 267         |
| Glucose                                           | 524         | 373         | 356         | 350         | 408         | 239         | 368         | 278         |
| HDL cholesterol                                   | 228         | 239         | 200         | 250         | 306         | 199         | 329         | 207         |
| Potassium                                         | 341         | 167         | 157         | 309         | 203         | 97          | 165         | 135         |
| Total bilirubin                                   | 154         | 139         | 100         | 94          | 143         | 95          | 103         | 56          |
| Triglycerides                                     | 317         | 361         | 333         | 338         | 423         | 199         | 348         | 275         |
| Urea                                              | 381         | 112         | 91          | 145         | 117         | 212         | 285         | 56          |
| Uric acid                                         | 313         | 340         | 329         | 173         | 363         | 183         | 293         | 265         |
| Anemia profile                                    |             |             |             |             |             |             |             |             |
| Iron                                              | 102         | 207         | 86          | 89          | 100         | 52          | 185         | 73          |
| Ferritin                                          | 92          | 146         | 87          | 87          | 118         | 45          | 121         | 110         |
| Transferrin                                       | 38          | 15          | 59          | 12          | 78          | 10          | 34          | 19          |
| Rheumatic profile                                 |             |             |             |             |             |             |             |             |
| C-reactive protein                                | 167         | 147         | 54          | 58          | 115         | 110         | 71          | 75          |
| Calcium                                           | 156         | 43          | 284         | 100         | 129         | 44          | 68          | 37          |
| Phosphate                                         | 85          | 37          | 253         | 95          | 86          | 30          | 40          | 32          |
| Rheumatoid factor                                 | 24          | 33          | 57          | 64          | 31          | 26          | 44          | 42          |
| Thyroid profile                                   |             |             |             |             |             |             |             |             |
| Free thyroxine                                    | 95          | 110         | 42          | 18          | 68          | 117         | 74          | 42          |
| Thyrotropin                                       | 152         | 140         | 160         | 82          | 226         | 117         | 147         | 100         |
The daily LIS registers (tests requested by GPs) were collected and indicators were calculated using a computer application based on data warehouse and OnLine Analytical Processing (OLAP) cubes (Omnium, Roche Diagnostic, Spain). Every test request per 1,000 inhabitants (22 chemistry tests) and the appropriate indicators that measured the number of tests per related test requested (aspartate aminotransferase/alanine aminotransferase, urea/creatinine, free thyroxine/thyrotropin) by GPs were calculated.

The savings generated, if each Health Care Department achieved the appropriate indicator standard (0.2 for aspartate aminotransferase/alanine aminotransferase, 0.1 for urea/creatinine, and 0.25 for thyroxine/thyrotropin), were also calculated (5).

### Results

Table I shows the test requests per 1,000 inhabitants per Health Care Department in 2009 grouped according to the tests most used in primary care. There was a large difference in demand for tests by health areas.

The appropriate indicators (ratio of related tests) are shown in Table II. The ratio of related tests also showed a great variability.

The savings generated, if each Health Care Department had achieved the appropriate indicator standard, were €253,083: €18,289 for aspartate aminotransferase, €62,678 for urea, and €172,116 for thyroxine.

### Discussion

Studies to evaluate clinical laboratory activities are a tool increasingly used to compare performance between organizations using the same measures and the same measurement system. It took 2 years to set up the laboratory network and data collection process and to identify suitable indicators for comparing primary care requesting performance.

Primary care demand for tests is growing (6) in terms of requests per inhabitant or per doctor. Our results demonstrate the broad variability of demand for tests by primary care on a test-by-test basis. It is not easy to establish a relationship between variability and center characteristics. All departments participating in the study, except one, are in an urban and coastal zone and are also influenced by seasonal tourism. The Valencian Community ranks the fourth most populated autonomous community of Spain, in a very populated country. There is no significant difference between the percentages of population aged >65 years in different centers. Five hospitals are university hospitals, but it is not possible to establish a relationship between the indicator values and the type of hospital.

It is strange to observe the great differences in serum glucose requesting, and the duplicated demand for potassium and sodium (the sodium results were not reported because they were identical to the potassium in all Health Care Departments) from one health area to another, where the prevalence of hypertension and need for monitoring are probably similar. Probably, different uses of lipids and uric acid measurements in the prevention of hypercholesterolemia and metabolic syndrome, respectively, will be responsible for large differences in requests (7). Moreover, uric acid is requested out of habit. In addition, despite evidence to the contrary, most GPs believe that an annual physical examination detects subclinical illness (8). Many report using laboratory tests for screening purposes with little evidence to support the practice, although it has become less frequent (9) as evidence-based guidelines have come into use and medical cost containment has become a concern.

Larsson et al. (5) recommend using serum alanine aminotransferase and alkaline phosphatase as the only liver markers and demonstrated the enormous savings that would result from reducing demand for aspartate aminotransferase, bilirubin, and gamma-glutamyltransferase, which varied widely in the study.

Laboratory tests to diagnose anemia are subject to both under-use and over-use (10). It is well known

| Health care areas | A  | B  | C  | D  | E  | F  | G  | H  |
|------------------|----|----|----|----|----|----|----|----|
| **Key Performance Indicator (KPI)** |  |    |    |    |    |    |    |    |
| Aspartate amino transferase / Alanine amino transferase | 0.435 | 0.611 | 0.404 | 0.372 | 0.246 | 0.962 | 1.000 | 1.000 |
| Urea / Creatinine | 0.725 | 0.285 | 0.283 | 0.455 | 0.298 | 0.968 | 0.918 | 0.198 |
| Free thyroxine / Thyrotropin | 0.587 | 0.701 | 0.269 | 0.255 | 0.306 | 1.000 | 0.504 | 0.419 |
that iron alone should not be ordered as part of an anemia investigation. However, it is surprising that certain departments are requesting from 3 to 10 times more iron than transferrin tests. Despite the iron test being cheap, its uselessness as an isolated test and the high within-person biological variation of serum iron indicate that early establishment of corrective measures is required to reduce its isolated request and to highlight the need for iron and transferrin to be used in combination. It is an archaic habit, important to change soon.

The variability in requests for rheumatic and thyroid disease tests is also noteworthy; for instance, free thyroxin is requested despite evidence that it may be generated after abnormal thyrotropin in primary care patients. There is also a huge difference in the requesting patterns of calcium, possibly an ‘under-used’ test in some areas. Treatable primary hyperparathyroidism disease in patients who are generally free of somatic manifestations is most often diagnosed when routine biochemical testing shows an elevated serum calcium level. The advent of automated laboratory serum analyzers in the 1960s allowed for the detection of ‘asymptomatic hypercalcemia’, and the incidence of hyperparathyroidism increased 5-fold during the next two decades. However, nowadays hyperparathyroidism can be again overlooked due to the disappearance of analyzers of continuous type. Calcium is a parameter whose use should be encouraged.

Probably, high demand for C-reactive protein tests in area A indicated more frequent use to detect/monitor infectious/rheumatoid diseases, when compared to other areas.

In certain health areas, urea and creatinine requests were similar, and transferrin requests were identical (1:1 demand ratio). However, there is evidence indicating that serum urea provides little more information than serum creatinine alone (11), as also applies to the two transferases. We only studied the economic effects of decreasing three serum chemistry test ratios, and the total savings would be great. If we use these figures to calculate the total savings for all health care areas in Valencian Community, and more tests ratios, it would represent an enormous saving.

The great differences observed in the study in all test requests in such a large population are inconsistent with the goal of providing equitable care and apparently reflect local traditions (5). The differences are probably due to individual variations in clinical practice; however, they still undermine laboratory cost-effectiveness efforts and could be changed (12), preferably through regional strategies developed by consensus between GPs and clinical pathologists and formalized in health care governance measures.

Given the large difference in requesting patterns between health areas, the first step in optimizing laboratory test use would be to establish basic reflex testing strategies. Implementation of these measures would then be monitored using appropriate indicators, which actually vary greatly from one district to another, after setting clear goals. Nowadays most tests are added by automated analysers in accordance with algorithms. Previous process mapping will be needed in less automated laboratories. Laboratory directors should be aware that any strategy implemented to reduce inappropriate test use will reduce the number of tests processed by personnel and will appear to diminish theoretical performance. However, high-quality diagnostic information would be obtained. In addition, unexpected results and false positives would decrease, and, concomitantly, so would the number of diagnostic tests performed and specialist consultations required for their interpretation, which are an important source of anxiety for patients. This is where the contribution of laboratory professionals is critical, by providing fewer, more selective, optimally effective diagnostic data.

Laboratory data are involved in 70% of clinical decisions (13); however, laboratory costs usually account for a very small proportion of overall health care costs. Patients should receive the full benefit from laboratory medicine, and it is important to encourage the use of some tests, such as serum calcium.

This study revealed that considerable variability exists in the use of laboratory tests by eight health areas. It also identified appropriate indicators that can be applied across a spectrum of clinical laboratories, and which thus may be useful for examining requesting patterns. The study highlighted the need to unify demand by optimizing the use of appropriate tests through interdepartmental communication and rigorous application of scientific evidence (14).

**Declaration of interest:** The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

**References**

1. Mindemark M, Larsson A. Longitudinal trends in laboratory test utilization at a large tertiary care university hospital in Sweden. Ups J Med Sci. 2011;116:34–8.
2. Plebani M. Laboratory medicine: value for patients is the goal. Clin Chem. 2007;53:1873–4.
3. Bossuyt X, Verweire K, Blanckaert N. Laboratory medicine: challenges and opportunities. Clin Chem. 2007;53:1730–3.
4. Van Walraven C, Naylor CD. Do we know what inappropriate laboratory utilization is? A systematic review of laboratory clinical audits. JAMA. 1998;280:550–8.
5. Larsson A, Palmer M, Hultén G, Tryding N. Large differences in laboratory utilisation between hospitals in Sweden. Clin Chem Lab Med. 2000;38:383–9.
6. Smellie WSA. Appropriateness of test use in pathology: a new era or reinventing the wheel? Ann Clin Biochem. 2003;40:585–92.
7. Lohsoonthorn V, Dhanamum B, Williams MA. Prevalence of hyperuricemia and its relationship with metabolic syndrome in Thai adults receiving annual health exams. Arch Med Res. 2006;37:883–9.
8. Prochazka AV, Lundahl K, Pearson W, Oboler SK, Anderson RJ. Support of evidence-based guidelines for the annual physical examination: a survey of primary care providers. Arch Intern Med. 2006;166:368.
9. Chacko KM, Feinberg LE. Laboratory screening at preventive health exams: trend of testing, 1978–2004. Am J Prev Med. 2007;32:59–62.
10. Wheeler LA, Brecher G, Sheiner LB. Clinical laboratory use in the evaluation of anemia. JAMA. 1977;238:2709–14.
11. Winkens RA, Pop P, Grol RP, Kester AD, Knotnerus JA. Effect of feedback on test ordering behaviour of general practitioners. BMJ. 1992;304:1093–6.
12. Smellie WSA, Galloway MJ, Chinn D, Gedling P. Is clinical practice variability the major reason for differences in pathology requesting patterns in general practice? J Clin Pathol. 2002;55:312–4.
13. Salinas M, López-Garrigós M, Uris J. Towards laboratory knowledge, not data, in 70% of clinical decision-making. What “knowledge management” can add to clinical practice? Clin Chem Lab Med. 2011;49:1389–90.
14. Trenti T. Evidence-based laboratory medicine as a tool for continuous professional improvement. Clin Chim Acta. 2003; 333:155–67.